<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948645</url>
  </required_header>
  <id_info>
    <org_study_id>M20-405</org_study_id>
    <nct_id>NCT04948645</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calico Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Calico Life Sciences LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic&#xD;
      Lateral Sclerosis. This is a 48-week, 2-part study. Part 1 will be a 4-week, randomized,&#xD;
      double-blind, placebo-controlled study; Part 2 will be a 44-week active treatment extension&#xD;
      (ATE) during which all subjects will receive ABBV-CLS-7262.&#xD;
&#xD;
      Subjects will attend regular visits during the course of the study and complete medical&#xD;
      assessments, blood tests, checking for side effects, and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline Up to Approximately Day 28</time_frame>
    <description>Number of patients with treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Baseline Up to Approximately Day 28</time_frame>
    <description>Maximum Plasma Concentration [Cmax]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Baseline Up to Approximately Day 28</time_frame>
    <description>Area Under the Curve [AUC]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF Pharmacokinetics</measure>
    <time_frame>Baseline Up to Approximately Day 28</time_frame>
    <description>Concentration at steady state in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline Up to Approximately Week 48</time_frame>
    <description>Number of patients with treatment-related adverse events as assessed by CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ALS</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ABBV-CLS-7262 LOW DOSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-CLS-7262 MEDIUM DOSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-CLS-7262 HIGH DOSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-CLS-7262</intervention_name>
    <description>Oral</description>
    <arm_group_label>ABBV-CLS-7262 HIGH DOSE</arm_group_label>
    <arm_group_label>ABBV-CLS-7262 LOW DOSE</arm_group_label>
    <arm_group_label>ABBV-CLS-7262 MEDIUM DOSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have an identified, reliable caregiver&#xD;
&#xD;
          -  Confirmed diagnosis of Familial ALS or Sporadic ALS&#xD;
&#xD;
          -  First ALS symptoms occurred ≤36 months before screening&#xD;
&#xD;
          -  Able to swallow solids&#xD;
&#xD;
          -  No known active COVID-19 infection at screening&#xD;
&#xD;
          -  Vital capacity ≥50% predicted value (for sex, age, ethnic origin, and height) at&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of dementia/severe cognitive problems at screening&#xD;
&#xD;
          -  Use of riluzole (Rilutek®) at a dose which has NOT been stable for &gt;1 months prior to&#xD;
             Baseline.&#xD;
&#xD;
          -  Use of edaravone (Radicava®) within 1 month prior to screening or intention of&#xD;
             initiating edaravone within 3 months after receiving the first dose of ABBV-CLS-7262.&#xD;
&#xD;
          -  History of clinically significant medical conditions (other than ALS) or any other&#xD;
             reason, including any physical, psychological, or psychiatric condition that, in the&#xD;
             opinion of the Investigator, would compromise the safety or interfere with the&#xD;
             subject's participation in the study, or would make the subject an unsuitable&#xD;
             candidate to receive study drug, or would put the subject at risk by participating in&#xD;
             the study.&#xD;
&#xD;
          -  History of abnormal screening laboratory or imaging results that, in the opinion of&#xD;
             the Investigator, are indicative of any significant cardiac, endocrinologic,&#xD;
             hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary,&#xD;
             gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major&#xD;
             disease that would preclude administration of ABBV-CLS-7262.&#xD;
&#xD;
          -  If female, is known to be pregnant, breastfeeding, considering becoming pregnant, or&#xD;
             donating/banking eggs during the study or within 30 days or &gt;5 half-lives (whichever&#xD;
             is longer) after the last dose of study drug&#xD;
&#xD;
          -  If male, plans to donate sperm or father a child during the study or within 30 days&#xD;
             after the last dose of study drug.&#xD;
&#xD;
          -  Known to have received any investigational product within 30 days or 5 half-lives of&#xD;
             the drug (whichever is longer) prior to the first dose of study drug or is currently&#xD;
             enrolled in another clinical study.&#xD;
&#xD;
          -  History of ABBV-CLS-7262 use prior to participation in this study&#xD;
&#xD;
          -  Recent (within 6 months prior to Screening) history of drug or alcohol abuse&#xD;
&#xD;
          -  Previous participation in a stem cell clinical study&#xD;
&#xD;
          -  Current or anticipated use of diaphragmatic pacing during the study period&#xD;
&#xD;
          -  Tracheostomy or use of non-invasive ventilatory support ≥22 hours a day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Calico Call Center</last_name>
    <phone>1-844-463-2423</phone>
    <email>CalicoALS@patientrm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horizon Health Network</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 4R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

